December 2025

Breyanzi-outcomes in 2L treatment of Aggressive B-Cell Lymphoma¹

Discover the results from 18 month follow-up of the TRANSFORM study, which investigates the efficacy and safety of Breyanzi, CAR-T therapy, vs earlier standard of care (SOC) with 3 cycles of platinum-based immunochemotherapy followed by highdose chemotherapy and ASCT, as a second-line treatment for patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B).

Results: Median EFS was not reached (NR) for Breyanzi vs 2.4 months for SOC. Complete response (CR) rate was 74 % for Breyanzi vs 43 % for SOC (P < 0.0001) and median progression-free survival (PFS) was not reached for Breyanzi vs 6.2 months for SOC (HR = 0.400; P < 0.0001). Median overall survival was not reached for Breyanzi vs 29.9 months for SOC (HR = 0.724; P = 0.0987). Grade 3 cytokine release syndrome and neurological events occurred in 1% and 4% of patients with Breyanzi, with no grade 4 or 5 events.

Conclusion: These data show significant improvements in EFS, CR rate and PFS for Breyanzi compared with SOC and support Breyanzi as a preferred second-line treatment in patients with primary refractory or early relapsed LBCL.

References:

1. Abramson et al, Blood (2023) 141 (14): 1675–1684.